1-3 of 3
James D. Hilger, Ph.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard Klein, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD
Journal: Blood
Blood (2013) 122 (21): 3218.
https://doi.org/10.1182/blood.V122.21.3218.3218
Published: 2013
Journal Articles

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

James R. Berenson, MD, James D. Hilger, Ph.D., Robert Dichmann, MD, Dipti Patel-Donnelly, MD, Ralph V. Boccia, MD, Alberto Bessudo, MD, Laura V. Stampleman, MD, Donald S. Gravenor, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD
Journal: Blood
Blood (2012) 120 (21): 4063.
https://doi.org/10.1182/blood.V120.21.4063.4063
Published: 2012
Journal Articles

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard M. Klein, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD
Journal: Blood
Blood (2012) 120 (21): 2979.
https://doi.org/10.1182/blood.V120.21.2979.2979
Published: 2012